Pillsbury Lake Capital LLC Takes $828.67 Million Position in MiMedx Group, Inc $MDXG

Pillsbury Lake Capital LLC bought a new position in shares of MiMedx Group, Inc (NASDAQ:MDXG) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 215,239 shares of the company’s stock, valued at approximately $828,670,000.

Other hedge funds have also bought and sold shares of the company. Sunbelt Securities Inc. purchased a new position in shares of MiMedx Group during the 1st quarter valued at approximately $42,000. E Fund Management Co. Ltd. acquired a new stake in MiMedx Group during the second quarter valued at $45,000. Legal & General Group Plc acquired a new stake in MiMedx Group during the second quarter valued at $45,000. Kemnay Advisory Services Inc. purchased a new position in MiMedx Group in the fourth quarter valued at $48,000. Finally, Williams & Novak LLC acquired a new position in shares of MiMedx Group in the second quarter worth about $53,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on MDXG shares. Raymond James Financial set a $8.00 target price on MiMedx Group in a research report on Monday, August 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 price target on shares of MiMedx Group in a research report on Monday, August 17th. Wall Street Zen lowered MiMedx Group from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of MiMedx Group in a research note on Thursday, August 13th. Finally, Citizens Jmp decreased their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Thursday, April 30th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $8.43.

MiMedx Group Price Performance

NASDAQ:MDXG opened at $4.42 on Thursday. The stock has a 50 day moving average price of $4.15 and a 200 day moving average price of $4.10. The stock has a market cap of $644.26 million, a PE ratio of 110.53 and a beta of 1.45. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.79 and a current ratio of 5.33. MiMedx Group, Inc has a one year low of $3.03 and a one year high of $7.97.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $64.36 million during the quarter, compared to the consensus estimate of $63.46 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. Equities research analysts expect that MiMedx Group, Inc will post -0.1 EPS for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.